NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 239 filers reported holding NEKTAR THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $43,665 | +87230.0% | 73,313 | -16.5% | 0.00% | 0.0% |
| Q2 2023 | $50 | -18.0% | 87,786 | +1.1% | 0.00% | -25.0% |
| Q1 2023 | $61 | -69.7% | 86,862 | -2.3% | 0.00% | -66.7% |
| Q4 2022 | $201 | -100.0% | 88,904 | -60.1% | 0.01% | -74.5% |
| Q3 2022 | $714,000 | -19.6% | 223,047 | -4.6% | 0.05% | -14.5% |
| Q2 2022 | $888,000 | -50.0% | 233,768 | -29.0% | 0.06% | -41.5% |
| Q1 2022 | $1,775,000 | -57.6% | 329,308 | +6.4% | 0.09% | -54.1% |
| Q4 2021 | $4,183,000 | -18.2% | 309,632 | +8.8% | 0.20% | -23.8% |
| Q3 2021 | $5,112,000 | +1.4% | 284,612 | -3.1% | 0.27% | 0.0% |
| Q2 2021 | $5,043,000 | -4.7% | 293,854 | +11.0% | 0.27% | -15.4% |
| Q1 2021 | $5,294,000 | – | 264,701 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |